Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

AbbVie Inc. researches and develops pharmaceutical products. The Company produces pharmaceutical drugs for specialty therapeutic areas such as immunology, chronic kidney disease, hepatitis C, women"s health, oncology, and neuroscience. AbbVie also offers treatments for diseases including multiple sclerosis, parkinson"s, and alzheimer"s disease.
Website: abbvie.com


  • Bad financial results growth rate -23.0% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (10.7%)
  • Dividend yield for the last twelve months 3.3%
  • Free cash flow yield -0.4% (LTM)
  • Share price is 73.1% higher than minimum and 0.0% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (19.9x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $79.4 mln (-0.025% of cap.)

Key Financials (Download financials)

Ticker: ABBV  postmarket  182.37  (+0.1%)
Share price, USD:  (+1.0%)182.1
year average price 152.53  


year start price 159.37 2023-03-31

min close price 132.51 2023-06-28

max close price 182.10 2024-03-28

current price 182.10 2024-03-29
Common stocks: 1 768 480 508

Dividend Yield:  3.3%
FCF Yield LTM: -0.4%
EV / LTM EBITDA: 19.9x
EV / EBITDA annualized: 23.7x
Last revenue growth (y/y):  -5.4%
Last growth of EBITDA (y/y):  -40.5%
Historical revenue growth:  7.6%
Historical growth of EBITDA:  13.7%
Target EV / EBITDA (hist percentile):
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 322 040
Net Debt ($m): 55 400
EV (Enterprise Value): 377 440
EBITDA LTM ($m): 18 927
EV / LTM EBITDA: 19.9x
Price to Book: 31.1x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2024-03-26Proactive Investors

AbbVie acquisition signals confidence in small-cap biotech sector's growth potential

2024-03-26Zacks Investment Research

AbbVie (ABBV) to Buy Landos to Strengthen Autoimmune Portfolio

2024-03-25Zacks Investment Research

AbbVie (ABBV) Advances While Market Declines: Some Information for Investors

2024-03-25Zacks Investment Research

Why AbbVie (ABBV) is a Great Dividend Stock Right Now

2024-03-25Zacks Investment Research

Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know

2024-03-25Reuters

AbbVie to buy Landos to expand pipeline of immunity-related illnesses

2024-03-24Seeking Alpha

Aldeyra: Derisked Biotech Eyeing Path To Approval And Finalizing Deal With AbbVie

2024-03-22Forbes

AbbVie's New ‘Biological Missile' Ovarian Cancer Treatment Gets Full FDA Approval

2024-03-22Reuters

US FDA grants full approval to AbbVie's ovarian cancer therapy

2024-03-19Zacks Investment Research

AbbVie (ABBV) Exceeds Market Returns: Some Facts to Consider
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data